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Abstract
Antizyme (AZ) is a protein with 228 amino acid residues that regulates ornithine decarboxylase (ODC) by binding to ODC
and dissociating its homodimer, thus inhibiting its enzyme activity. Antizyme inhibitor (AZI) is homologous to ODC, but has
a higher affinity than ODC for AZ. In this study, we quantified the biomolecular interactions between AZ and ODC as well as
AZ and AZI to identify functional AZ peptides that could bind to ODC and AZI and inhibit their function as efficiently as the
full-length AZ protein. For these AZ peptides, the inhibitory ability of AZ_95-228 was similar to that of AZ_WT. Furthermore,
AZ_95-176 displayed an inhibition (IC50: 0.20 mM) similar to that of AZ-95-228 (IC50: 0.16 mM), even though a large segment
spanning residues 177–228 was deleted. However, further deletion of AZ_95-176 from either the N-terminus or the C-
terminus decreased its ability to inhibit ODC. The AZ_100-176 and AZ_95-169 peptides displayed a noteworthy decrease in
ability to inhibit ODC, with IC50 values of 0.43 and 0.37 mM, respectively. The AZ_95-228, AZ_100-228 and AZ_95-176
peptides had IC50 values comparable to that of AZ_WT and formed AZ-ODC complexes with Kd,AZ-ODC values of 1.5, 5.3 and
5.6 mM, respectively. Importantly, our data also indicate that AZI can rescue AZ peptide-inhibited ODC enzyme activity and
that it can bind to AZ peptides with a higher affinity than ODC. Together, these data suggest that these truncated AZ
proteins retain their AZI-binding ability. Thus, we suggest that AZ_95-176 is the minimal AZ peptide that is fully functioning
in the binding of ODC and AZI and inhibition of their function.
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Introduction
Polyamines such as putrescine, spermidine, and spermine can
bind to DNA, RNA, and proteins to control a variety of
physiological functions including DNA replication, gene regula-
tion, cell cycling, apoptosis, post-translational modification and
protein synthesis [1–3]. Elevated polyamine levels cause cell
growth and differentiation in eukaryotes and thus may be highly
associated with the development of cancer [2,4–6]. Ornithine
decarboxylase (ODC, EC 4.1.1.17) is a pyridoxal 59-phosphate
(PLP)-requiring enzyme that catalyzes the decarboxylation of L-
ornithine to putrescine. ODC is the first and rate-limiting enzyme
for polyamine biosynthesis [4,7–8]. Due to the fact that elevated
ODC activity increases polyamine levels in cells and that
overexpression of ODC is associated with neoplastic transforma-
tion of cells [9–12], ODC is considered an oncogenic enzyme [7].
Therefore, inhibitors of ODC and the polyamine synthesis
pathway have excellent therapeutic potential for many cancers
[2,5,12–13].
Human ODC is a homodimer containing 461 amino acid
residues with a molecular weight of 53 kDa per monomer [14].
ODC can be up-regulated by the c-myc and ras oncogenes [15] and
is degraded within minutes through a process controlled by its
regulatory protein, antizyme (AZ) [16]. The first mammalian AZ
was discovered in 1976 [17]. Proteins are usually degraded
through the ubiquitination pathway. However, ODC uniquely
undergoes ubiquitin-independent degradation through non-cova-
lent interactions with AZ [1,16,18]. The binding of AZ to ODC
causes the dissociation of ODC dimers to produce AZ-ODC
heterodimers, thus abolishing enzyme activity [7,19–20]. Further-
more, the binding of AZ stimulates a conformational change in
ODC that causes the enzyme to expose its C-terminal tail for
recognition by 26S proteasome [21–23].
AZ was the first protein found to utilize translational frame
shifting in the regulation of mammalian mRNA [19,24]. Increased
concentrations of polyamines induce the ribosome to bypass the
first open reading frame (ORF) of AZ and allow the second ORF
(+1 frame-shift) to synthesize a 228 amino acid residues with a
molecular weight of 22-kDa, fully functional AZ protein [24–25].
AZ is regarded as a tumor suppressor gene because it inhibits
ODC activity and polyamine transport and hinders many cancers
caused by abnormal ODC and polyamine levels [1,18–19,26–28].
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polyamine interferes with AZ degradation [29–30].
There are at least four AZ isozymes with different binding
affinities for ODC [31–32]. Isoform 1, AZ-1, is present in all
tissues and is the major isoform that participates in ODC
degradation. The NMR structure of rat AZ-1 (residues 87–227)
shows that it contains eight b-strands, b1–b8, and two a-helices, a1
and a2 [33]. The C-terminal region of AZ-1 interacts with ODC
to inhibit enzyme activity, and the N-terminal region of AZ-1
controls the degradation of ODC [34–36]. AZ-2 has a distribution
similar to that of AZ-1 in all of the tissues and cells examined thus
far, but its expression level is significantly lower than that of AZ-1
[37]. Although AZ-2 can inhibit ODC enzyme activity, it does not
promote ODC degradation, suggesting that it plays a role as a
reversible storage compartment for stabilizing the ODC monomer
by forming a heterodimer [38–39]. AZ-3 has tissue specificity in
the germ cells of testes, where expression is restricted to the post-
meiotic stage of spermatogenesis during the differentiation of male
germ cells to mature sperm [40]. Male infertility has been linked to
ODC overexpression in transgenic mice, implying that AZ-3 may
play an important role in controlling ODC levels in male
infertility. AZ-3 poorly inhibits ODC activity and fails to stimulate
ODC degradation, but is similar to AZ-1 and AZ-2 in polyamine
transportation [41]. AZ-4 has been found in the human brain and
can also inhibit ODC activity, but its ability to stimulate ODC
degradation and its role in polyamine uptake are still unknown
[42].
Another protein that regulates ODC by binding to AZ is called
antizyme inhibitor (AZI). AZI is homologous to ODC, but lacks
ODC enzymatic activity [32,43–46]. It binds to AZ with a higher
affinity than ODC to sequester AZ from the AZ-ODC
heterodimer and thus rescues ODC activity from AZ suppression
and prevents rapid ODC degradation [20,46–48]. AZI can bind to
all isoforms of mammalian AZ [32,42]. Overexpression of AZI
Figure 1. Homology model of human antizyme. (A) A homology model of human AZ using the NMR structure of rat AZ as the template [51].
(B) The secondary structure elements of human AZ from 95–228 consisting of two a-helices and eight b-strands. (C) A diagram of all truncated AZ
peptides.
doi:10.1371/journal.pone.0024366.g001
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proliferation and transformation [49–50], suggesting that AZI is
also an oncogenic protein [46].
Because AZ appears to act as a tumor suppressor, it may be a
good target for anticancer therapy. In this study, we focus on the
biomolecular interactions between AZ and ODC as well as AZ
and AZI to identify functional AZ peptides that could bind to
ODC and AZI and inhibit their function as efficiently as the full-
length AZ protein. Since many peptides, such as insulin, are used
as drugs, fully functional AZ peptides may be used as candidates
for anticancer therapy and these data may provide further
information to guide drug designs of ODC and AZI.
Results
Inhibition of ODC enzyme activity by the AZ peptide
A homology model of the human AZ structure was created
using the NMR structure of mouse AZ as the template (Figure 1A,
ESyPred3D: http://www.fundp.ac.be/sciences/biologie/urbm/
bioinfo/esypred/) [51]. According to the secondary structure
elements of AZ, we designed a series of AZ peptides to examine
their ability to bind to ODC (Figures 1B and C). We first
examined the inhibitory effect of these AZ peptides toward ODC
enzyme activity (Figure 2) and calculated the IC50 values for these
AZ peptides (Table 1).
In the inhibition experiments, these AZ peptides displayed a
differential inhibition ability that appeared to correlate with their
length. The inhibition ability of the AZ_87-228 peptide was
similar to that of AZ_WT but greater than that of AZ_87-124,
indicating the importance of the C-terminus of AZ in binding to
ODC (Figure 2A). The IC50 values for AZ_WT, AZ_87-228 and
AZ_87-124 were 0.16, 0.17 and 0.52 mM, respectively. We further
constructed AZ peptides from residue 95 to different ends of the
C-terminus (95-series). The inhibition ability of AZ_95-228 was
also similar to that of AZ_WT, and AZ_95-176 retained most of
the inhibition ability, even though a large segment of 177–228 was
deleted (Figure 2B). The IC50 values for AZ_95-228 and AZ_95-
176 were similar to each other at 0.16 and 0.20 mM, respectively.
However, a further deletion of AZ_95-176 from the C-terminus
decreased the inhibition efficiency of AZ. The AZ_95-169 peptide,
lacking b-strand 6 (b6), was only seven residues shorter than
AZ_95-176, yet displayed a noteworthy decrease in ODC
inhibition ability. The IC50 value of AZ_95-169 was 0.37 mM,
2.3-fold larger than that of AZ_WT. This indicates that b6
(residue 171–176) may contribute to ODC enzyme inhibition.
Successive deletion of AZ_95-169 from C-terminus continued to
reduce the inhibition ability of AZ. The IC50 values for AZ_95-
135 and AZ_95-124 were 0.51 and 0.65 mM, respectively
(Table 1).
Deletion from the N-terminus of AZ to different ends of the C-
terminus was also performed (Figure 2C). AZ peptides from
residue 100 (100-series) were constructed to compare with the 95-
series of AZ peptides. The inhibition ability of AZ_100-228 was
similar to that of AZ_WT and AZ_95-176 (Figures 2B and C); the
IC50 value of AZ_100-228 was 0.21 mM. However, unlike AZ_95-
176, which had an inhibition ability similar to that of AZ_95-228,
the AZ_100-176 peptide had a lower inhibition ability than that of
Figure 2. Relative ODC enzyme activity in the presence of AZ
peptides. The activity of ODC was inhibited by various concentrations
of AZ peptides. ODC concentrations were fixed at 20 mg/mL (0.19 mM).
The IC50 values of AZ peptides shown in Table 1 were derived from
fitting these inhibition curves. The molar ratio refers to AZ peptide
versus ODC monomer.
doi:10.1371/journal.pone.0024366.g002
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0.43 mM, 2.6-fold larger than that of AZ_WT. Successive deletion
of AZ_100-176 from C-terminus continued to reduce the
inhibition ability of AZ. The AZ_100-135 and AZ_100-124
peptides displayed notably weaker inhibition ability than AZ_100-
228 (Figure 2C). The IC50 values for AZ_100-135 and AZ_100-
124 were 0.86 and 0.82 mM, respectively (Table 1).
The N-terminal truncation of AZ demonstrated relatively poor
inhibition (Figure 2D). AZ_106-228 showed weaker inhibition
ability than AZ_100-228 (Figures 2C and D), suggesting the
importance of b-strand 2 (b2). Further deletion from the N-
terminus to residue 113 (AZ_114-228) and to residue 125
(AZ_126-228) continued to impair the ability of AZ to inhibit
ODC, as the IC50 values for AZ_106-228, AZ_114-228 and
AZ_126-228 were 0.37, 0.97 and 1.19 mM, respectively. Although
these AZ peptides had a reduced ability to inhibit ODC, they did
lessen enzyme activity at high concentrations of AZ (Figure 2). In
contrast, AZ_152-228 and AZ_177-228 showed almost no ODC
inhibition, even at high concentrations of AZ (Figure 2D).
Binding affinity of AZ peptides toward ODC
AZ binds ODC, dissociates the ODC dimer and then
inactivates the enzyme [19,20]. A size distribution analysis of
ODC in the presence of AZ displayed the formation of AZ-ODC
complexes (Figure 3A). In order to determine the differential
binding affinity of these AZ peptides toward ODC, the size
distributions of ODC with different concentrations of AZ peptides
were analyzed. All sedimentation data were globally fitted with the
AB hetero-association model in the SEDPHAT program to obtain
the dissociation constant (Kd) between ODC and AZ (Figure 3 and
Table 2). AZ_WT disrupted dimeric ODC to form AZ-ODC
complexes with a Kd,AZ-ODC value of 0.71 mM (Table 2). The
AZ_95-228, AZ_100-228 and AZ_95-176 peptides all had IC50
values similar to that of AZ_WT and formed AZ-ODC complexes
(Figures 3B–D, respectively) with Kd,AZ-ODC values of 1.5, 5.3 and
5.6 mM, respectively (2.1, 7.5 and 7.8-fold higher than that of
AZ_WT). In contrast, the peptides that showed weaker inhibition,
AZ_95-135, AZ_100-176, AZ_87-124 and AZ_95-124, formed
AZ-ODC complexes (Figures 3E and F) with Kd,AZ-ODC values of
10.3, 10.8, 12.7 and 18.6 mM, respectively (14.5 to 26.2-fold
higher than that of AZ_WT).
Binding ability of the AZ peptide for AZI
AZ has a greater affinity for AZI than ODC, such that the
formation of an AZ-AZI heterodimer will release the ODC
monomer from an AZ-ODC complex and rapidly restore ODC
enzyme activity [20]. Here, we examined the inhibition of ODC
enzyme activity by AZ peptides in the presence of AZI. The
ODC enzyme was first pre-incubated with AZI, keeping the
molar ratio of AZI monomer/ODC monomer at unity. In the
presence of AZI, ODC inhibition by AZ_WT and the AZ
peptides was lower than in the absence of AZI; more AZ
molecules were needed to inhibit ODC activity (Figure 4). Table 1
illustrates the IC50 values of the AZ peptides in the presence of
AZI, showing that all of the IC50 values for the AZ peptides with
AZI were larger than the values without AZI. The inhibition
plots of the AZ peptides with AZI (Figure 4I) clearly demonstrate
the differential inhibition ability among these AZ peptides. The
IC50 (with AZI) values of the AZ_95-228, AZ_100-228 and AZ_95-
176 peptides, at 0.57, 0.62 and 0.68 mM, respectively, were
similar to the IC50 (with AZI) of AZ_WT. Furthermore, the
IC50 (with AZI) values of the weaker inhibitors, AZ_87-124,
AZ_95-124, AZ_95-135 and AZ_100-176, were 1.55, 1.98, 1.59
and 1.42 mM, respectively. These data suggest that these AZ
peptides still conserved their binding ability toward AZI.
Interestingly, the ratio of IC50 (with AZI)/IC50 (without AZI) for these
AZ peptides remained constant around 3, implying the same
relative binding preference for ODC and AZI.
Table 1. IC50 values for AZ_WT and peptides.
AZ Peptide IC50 (mM) (without AZI)
IC50 (AZ peptide)/
IC50 (AZ_WT) IC50 (mM) (with AZI)
IC50 (with AZI)/
IC50 (without AZI)
WT 0.16 6 0.02 1.0 0.50 6 0.003 3.1
87-228 0.17 6 0.02 1.1 ND -
87-124 0.52 6 0.18 3.2 1.55 6 0.02 3.0
95-228 0.16 6 0.01 1.0 0.57 6 0.01 3.5
95-176 0.20 6 0.03 1.2 0.68 6 0.02 3.4
95-169 0.37 6 0.07 2.3 ND -
95-135 0.51 6 0.03 3.2 1.59 6 0.02 3.1
95-124 0.65 6 0.11 4.0 1.98 6 0.02 3.0
100-228 0.21 6 0.04 1.3 0.62 6 0.01 3.0
100-176 0.43 6 0.08 2.6 1.42 6 0.02 3.3
100-135 0.86 6 0.19 5.3 ND -
100-124 0.82 6 0.31 5.0 ND -
106-228 0.37 6 0.02 2.3 ND -
114-228 0.97 6 0.13 6.0 ND -
126-228 1.19 6 0.17 7.3 ND -
152-228 ND
a -N D -
177-228 ND - ND -
All IC50 values with or without AZI were derived from fitting the inhibition curves of ODC shown in Figures 2 and 4, respectively.
aND, not determined.
doi:10.1371/journal.pone.0024366.t001
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the dissociation constants for AZ peptide-AZI were also deter-
mined (Supplemental Figure S1, Table 2). Because AZI has a
higher affinity for AZ than ODC, the Kd values of these AZ-AZI
complexes (Kd,AZ-AZI) were smaller than those of the AZ-ODC
complexes (Kd,AZ-ODC). For AZ_WT, the Kd,AZ-AZI value of the
AZ-AZI heterodimer was 0.027 mM. For the peptides that had
Kd,AZ-ODC values similar to that of AZ_WT, AZ_95-228, AZ_100-
228 and AZ_95-176, the Kd,AZ-AZI values were 0.024, 0.068 and
0.06 mM, respectively. The AZ peptides with weaker binding
Figure 3. Continuous sedimentation coefficient distribution of human ODC in the presence of AZ peptide. The concentration of ODC
was fixed at 0.3 mg/mL with concentrations of AZ ranging from 0.015 to 0.2 mg/mL (the molar ratio of AZ/ODC ranged from 0.12 to 2) in a buffer of
30 mM Tris-HCl (pH 7.4) and 25 mM NaCl at 20uC. The sedimentation velocity data were globally fitted with the SEDTHAT program to obtain Kd
values for the AZ peptide-ODC complex (Table 2).
doi:10.1371/journal.pone.0024366.g003
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Kd,AZ-AZI values of 0.16 and 0.28 mM, respectively.
Discussion
AZ regulates ODC by binding to the enzyme, dissociating the
ODC homodimer and inhibiting ODC enzyme activity. Previous
studies of rat GST-AZ fusion protein have suggested that the C-
terminal segment, GST-AZ_106-212, is important for the binding
and inhibition of ODC [34]. Additionally, two functional regions
in rat MBP-AZ fusion protein, amino acids 211–218 and 122–144,
are considered to be important for the binding and inhibition of
ODC [35]. We are the first group using biochemical and
biophysical methods to demonstrate a minimal fully functional
human AZ peptide, AZ_95-176, which is sufficient for both the
inhibition of ODC enzyme activity and the binding of AZI. This
human AZ peptide is stable without fusion to any protein and is
shorter than those reported previously.
AZ_95-176 is the minimal AZ peptide fully functional for
binding and inhibition of ODC and AZI
Our data suggest that the N-terminus to amino acid 94 (1–94) is
not required for AZ binding or inhibition of ODC because AZ_95-
228 inhibits comparably to AZ_WT (Figure 2B, Table 2). Addition-
ally, we found that AZ_95-176 and AZ_100-228 are fully functional
and very similar to AZ_WT in binding and inhibition of ODC. The
overlapping region of these two peptides is AZ_100-176, and we
originally expected this fragment to be the minimal fully functional
AZ peptide.However,the inhibition by AZ_100-176 was not asgood
as that of AZ_95-176 or AZ_100-228. The AZ_95-176 peptide
comprises one a-helix and six b-strands, a1a n db1t ob6 while the
AZ_100-228 peptide consists of a1, a2a n db2t ob8 (Figure 1B). For
AZ_100-176, the lack of b1 may influence the structural conforma-
tion of the b-sheet, which may be required for AZ to interact with
ODC. Although AZ_100-228 also lacks b1, the two additional b-
strands, b7a n db8, may help to stabilize the structural conformation
of the b-sheet, thus preserving its ability to bind to ODC.
Therefore, we suggest that the AZ_95-176 peptide is the
minimal AZ peptide that is fully functional to bind and inhibit
ODC. The impaired inhibition of peptides AZ_95-169 and
AZ_100-176 support this inference. The deletion of amino acid
170 to 176 from the C-terminus (AZ_95-169) or the deletion of
amino acid 95 to 99 from the N-terminus (AZ_100-176) in AZ_95-
176 significantly decreases the ability of AZ in regards to the
inhibition and binding of ODC. Additionally, the inability of
AZ_177-228 to inhibit ODC activity also sustains this assumption.
In the AZ_100-228 peptide, the segment from residue 177 to 228
(secondary structure elements a2, b7 and b8) is required for
stability. However, this segment is not necessary for AZ
functioning, and the essential elements of AZ are not located
within this region because the AZ_177-228 peptide displays no
inhibition of ODC activity (Figure 2D).
Furthermore, we propose that the key elements of AZ for
binding AZI are the same as for ODC. AZI is homologous to
ODC, although it can inactivate AZ function through the tighter
binding of AZ, thus up-regulating ODC activity. Our data indicate
that AZI can rescue AZ peptide-inhibited ODC enzyme activity
(Figure 4). Furthermore, AZI can bind to AZ peptides with a
higher affinity than ODC (Table 2). These data demonstrate that
AZ-truncated proteins do not lose their AZI-binding ability,
supporting the idea that the same elements of AZ are utilized to
bind AZI and ODC. These AZ peptides may act as an antagonist
against AZI for rescue of the ODC enzyme activity.
The putative AZ-binding site of ODC and AZI is clasped
by the essential elements of AZ within amino acids
95–176
Docked structures of mouse AZ-ODC and AZ-AZI complexes
have been reported, and the docking results suggest that ODC and
AZI occupy the same binding site on AZ [52]. These docked
structures reveal that AZ binds within a large groove of ODC or
AZI (Figure 5). In the complex structure, residues 95–176 of AZ
face residues 117–140 of ODC, which is the putative AZ-binding
site, thus supporting the role of segment 95–176 of AZ in the
binding of ODC (Figure 5). However, a detailed structural view of
the interactions between AZ and ODC remains to be elucidated.
Anticancer therapy by blocking both ODC and AZI
activity
Our study has shown that a series of AZ peptides displayed
different efficiency in the binding of ODC and AZI and inhibition
of their function. These AZ peptides, which are specific to ODC
and AZI, may have low toxicity to cells and thus may have
potential in developing pharmaceutical products for use in
anticancer therapy. Further experiments regarding the effective-
ness of these AZ peptides in depressing internal polyamines
through the inhibition of polyamine biosynthesis and transport in
vivo are needed in the future.
Materials and Methods
Expression and purification of recombinant proteins
Human wild-type ODC, AZ and AZI and a series of truncated
AZ proteins were sub-cloned in the pQE30 vector (Qiagen) with
an N-terminal His6-Tag sequence for further purification. The
purification of these recombinant proteins were performed as
described in Su et al [20]. Briefly, the expression vector was
transformed into JM109 Escherichia coli (Stratagene). Protein
overexpression in JM109 was induced with 1 mM isopropyl-1-
thio-b-D-galactoside (IPTG) for 20 hr at 25uC. The crude extract
was applied to a His-Select
TM nickel affinity column (Sigma). The
lysate-Ni-NTA mixture was washed using buffer containing
10 mM imidazole, 500 mM NaCl, 1 mM b-mercaptoethanol
and 30 mM Tris-HCl at pH 7.6 to remove unwanted proteins.
Finally, the target protein was eluted with elution buffer (250 mM
imidazole, 500 mM NaCl, 30 mM Tris-HCl, and 1 mM b-
mercaptoethanol, pH 7.6). Protein concentrations were deter-
Table 2. Dissociation constants for human AZ-ODC and
AZ-AZI complexes.
AZ peptide Kd,AZ-ODC (mM) Kd,AZ-AZI (mM)
WT 0.71 6 0.005 0.027 6 0.0001
87-124 12.7 6 0.28 0.16 6 0.001
95-228 1.5 6 0.01 0.024 6 0.0002
95-176 5.6 6 0.04 0.06 6 0.004
95-135 10.3 6 0.07 ND
95-124 18.6 6 0.13 0.28 6 0.002
100-228 5.3 6 0.03 0.068 6 0.0007
100-176 10.8 6 0.07 ND
The dissociation constants (Kd) of AZ-ODC and AZ-AZI were derived from global
fitting of the sedimentation velocity data to the model of A+B«AB hetero-
association in the SEDTHAT program.
doi:10.1371/journal.pone.0024366.t002
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examined by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE).
Construction of AZ truncation mutants
A QuikChange
TM kit was used to generate the deletion of the
AZ gene (Stratagene, La Jolla). The primer for the truncated
mutant had to be at least 40 bases in length, with 15 bases on both
deletion sides to complement the template DNA. The primer
sequences for the truncations in the study were listed as follows:
87 (start) – 59-GGATCGCATCACCATCACCATCACGAT-
CACAATCTTTCAGC-39;
95 (start) – 59-GGATCGCATCACCATCACCATCACTTC-
TACTCCGATGATCG-39;
100 (start) – 59-GGATCGCATCACCATCACCATCACTTC-
TACTCCGATGATCG-39;
106 (start) – 59-GGATCGCATCACCATCACCATCAC-
GAACTAACGTCCAACGAC-39;
114 (start) – 59-GGATCGCATCACCATCACCATCACAG-
GATTCTCAACGTCCAG-39;
126 (start) – 59-GGATCGCATCACCATCACCATCA-
CAAACGCATTAACTGGCG-39;
152 (start) – 59-GGATCGCATCACCATCACCATCACAG-
CAAGGACAGCTTTGC-39;
177 (start) – 59-GGATCGCATCACCATCACCATCACCA-
CAAGAACCGCGAGG-39;
125 (stop) – 59-CCAGGCTCACAGACTAGAAACGCAT-
TAACTGGCG-39;
136 (stop) – 59-CGAACAGTGCTGAGTTAGGGCAGCC-
TCTACATCG-39;
170 (stop) – 59-GGAGCAGCTGCGAGCCTAGCATGTC-
TTCATTTGC-39;
177 (stop) –59-GTCTTCATTTGCTTCTAGAAGAACCGC-
GAGG-39. The mutant nucleotides are underlined and marked in
bold. The polymerase chain reaction (PCR) was performed using
Pfu DNA polymerase for a total of 16–18 cycles, and the product
was then digested with DpnI to cleave the wild-type DNA
template. Finally, the nicked DNA containing the desired
mutations was transformed into the XL-1 E. coli strain, and the
DNA sequence was verified by autosequencing.
ODC enzyme activity assay
The ODC enzyme activity was determined using a CO2-L3K
assay kit (DCL, Charlottetown, Canada) at 37uC. The continuous
measurement of ODC enzyme activity was coupled to the
carboxylation of PEP to oxaloacetate and the oxidation of
oxaloacetate to malate, as previously reported [20]. The reaction
mixture contains 30 mM Tris-HCl at pH 7.8, 10 mM ornithine,
0.2 mM pyridoxal 59-pyrophosphate and 0.4 ml of the CO2-L3K
assay kit solution, which contains 12.5 mM PEP, .0.4 U/ml
phosphoenolpyruvate carboxylase (microbial), .4.1 U/ml malate
dehydrogenase (mammalian) and 0.6 mM NADH analog in a
final volume of 0.5 ml.
For the AZ inhibition experiment, the ODC enzyme (0.19 mM)
and various amounts of AZ were added to the reaction mixture.
The reaction was started after the ODC was added, and the
absorbance decrease at 405 nm was continuously traced using a
Perkin-Elmer Lamba-25 spectrophotometer. In this coupled
reaction, the production of 1 mol of CO2 was concomitant with
the oxidation of 1 mol of NADH analog. An extinction coefficient
of 2410 M
21 was used for the NADH analog in the calculations.
To evaluate the inhibitory effect of AZ, the inhibited ODC
enzyme activity versus [AZ] was fitted with the following equation
to estimate the IC50 value:
ODC enzyme activity~Az B-A ðÞ
.
1z AZ ½  =IC50 ðÞ
Hill slope
h 
where A and B are the minimum and maximum ODC enzyme
activity, respectively, and the Hill slope gives the largest slope of
the curve. The IC50 value represents the concentration of AZ
required for 50% inhibition of ODC enzyme activity. All of the
calculations were done using the SigmaPlot 10.0 software program
(Jandel, San Rafael, CA).
For enzyme rescue experiments with AZI, the ODC enzyme
was first pre-incubated with AZ at a molar ratio of 3.5 AZ
monomers to 1 ODC monomer to achieve 80% enzyme
inhibition. The inhibited ODC activity was recovered by
increasing the AZI concentration.
Analysis of the AZ peptide-ODC complex size distribution
by analytical ultracentrifugation
A Beckman Optima XL-A analytical ultracentrifuge was used
for sedimentation velocity experiments. Reference and sample
Figure 5. Docked structure of the mouse AZ-ODC complex. The
molecular docking structure of the mouse AZ-ODC complex demon-
strates a heterodimer [52] consisting of an ODC monomer and an AZ
monomer. The putative AZ-binding site in ODC is colored yellow, and
segment 95–176 of AZ is purple. This figure was generated using
PyMOL (DeLano Scientific LLC, San Carlos, CA, USA).
doi:10.1371/journal.pone.0024366.g005
Figure 4. Relative ODC enzyme activities in the presence of AZ and AZI. ODC enzymes equilibrated with equimolar AZI were inhibited by
various concentrations of AZ peptides. The concentrations of AZI and ODC were fixed at 18.9 mg/mL and 20 mg/mL, respectively (the ratio of AZI
monomer versus ODC monomer was fixed at 1). Panels A–H show the inhibition curves of ODC for each AZ peptide in the absence (closed circles)
and in the presence (open circles) of AZI. Panel I displays the inhibition curves in the presence of AZI for different AZ peptides.
doi:10.1371/journal.pone.0024366.g004
Human Antizyme
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24366sectors in the centerpiece were filled with buffer (400 ml) and
sample protein (0.3 mg/mL, 380 ml), respectively, and then the
cell was built up in an An-50 Ti rotor. Sedimentation velocity
experiments were performed at 20uC with a rotor speed of
42,000 rpm. The data were traced by absorbance at 280 nm in
continuous mode, with a time interval of 420 s and a step size of
0.002 cm. A total of 20–30 scans at different time points were
collected and fitted to a continuous size distribution model using
the program SEDFIT [54–55]. All size distributions were
calculated at 0.1 to 20 S with a confidence level of p=0.95 and
a resolution N of 200.
In order to determine the dissociation constants (Kd) of the AZ
peptide-ODC and AZ peptide-AZI complexes, sedimentation
velocity experiments were performed at different concentrations of
AZ or AZ peptide with a constant concentration of human ODC
or AZI. The Kd values of the AZ peptide-ODC and AZ peptide-
AZI complexes were calculated by a global fitting of all
sedimentation data in the AB hetero-association model in the
SEDPHAT program [56–57]. The partial specific volumes of the
proteins, the solvent densities, and the viscosity were calculated by
the SEDNTERP program [58].
Supporting Information
Figure S1 Continuous sedimentation coefficient distri-
bution of human AZI in the presence of AZ peptide. The
concentration of AZI was fixed at 0.3 mg/mL with concentrations
of AZ ranging from 0.05 to 0.24 mg/mL (the molar ratio of AZ/
AZI ranged from 0.4 to 2.4) in a buffer of 30 mM Tris-HCl
(pH 7.4) and 25 mM NaCl at 20uC. The sedimentation velocity
data were globally fitted with the SEDTHAT program to obtain
Kd values for the AZ peptide-AZI complex (Table 2).
(TIF)
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